-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The reporter recently learned from the scientific research team of the joint prevention and control mechanism of the State Council and related scientific research teams that China adheres to multiple technical routes in parallel, and new progress
has been made in the research and development of new coronavirus vaccines.
has been made in the research and development of new coronavirus vaccines.
It is understood that three monovalent inactivated vaccines of the Omicron variant in China are undergoing sequential clinical trials in Chinese mainland, Hong Kong and the United Arab Emirates, and the trials are progressing smoothly
.
Nine multivalent vaccines involving variants have entered clinical trials, some of which are undergoing phase III clinical trials
.
At the same time, China is actively deploying and promoting the research and development of broad-spectrum vaccines
.
.
Nine multivalent vaccines involving variants have entered clinical trials, some of which are undergoing phase III clinical trials
.
At the same time, China is actively deploying and promoting the research and development of broad-spectrum vaccines
.
Recently, an inhaled adenovirus vector vaccine and a recombinant protein vaccine have been approved for sequential booster emergency use
in the specified population six months after completion of two doses of inactivated vaccine.
in the specified population six months after completion of two doses of inactivated vaccine.
Among them, the inhalation recombinant novel coronavirus vaccine (adenovirus vector type 5) is completed by oral inhalation, and the inhalation dose is about one-fifth
of the intramuscular injection dose.
The key data analysis results of phase III clinical trials of recombinant novel coronavirus fusion protein vaccine have shown that the use of the recombinant protein vaccine for sequential booster immunization on the basis of two injections of inactivated vaccine can produce good protection against new coronary pneumonia (mild and above) caused by Omicron variant infection and has good safety
.
of the intramuscular injection dose.
The key data analysis results of phase III clinical trials of recombinant novel coronavirus fusion protein vaccine have shown that the use of the recombinant protein vaccine for sequential booster immunization on the basis of two injections of inactivated vaccine can produce good protection against new coronary pneumonia (mild and above) caused by Omicron variant infection and has good safety
.
Experts from the Vaccine Research and Development Task Force of the Scientific Research Group of the Joint Prevention and Control Mechanism of the State Council said that in the face of the complex epidemic situation, vaccination is still an effective measure for
active immunization.
active immunization.
At present, 46 new coronavirus vaccines have entered clinical trials in China, 21 have been approved for phase III clinical trials overseas, 9 vaccines such as inactivated vaccines, adenovirus vector vaccines, and recombinant protein vaccines have been approved for conditional marketing or emergency use, and 3 vaccines have been included in the WHO emergency use list
.
.
